Iron Chelators in Neurodegenerative Disease

Iron Chelators in Neurodegenerative Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Iron Chelators in Neurodegenerative Disease</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Iron Chelators in Neurodegenerative Disease</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Iron Chelators in Neurodegenerative Disease

Overview

<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">Iron Chelators in Neurodegenerative Disease</th>
</tr>
<tr>
<td class="label">Name</td>
<td><strong>Iron Chelators in Neurodegenerative Disease</strong></td>
</tr>
<tr>
<td class="label">Type</td>
<td>Therapeutic</td>
</tr>
</table>

Iron chelation therapy represents a promising neuroprotective strategy for neurodegenerative diseases characterized by iron accumulation in the brain["@crapper1991"]. Iron dysregulation and oxidative stress are common pathological features in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative disorders["@ward2014"]. Iron chelators work by removing excess redox-active iron that would otherwise catalyze the production of toxic [reactive oxygen species](/entities/reactive-oxygen-species) (ROS), thereby potentially slowing disease progression.

Iron Homeostasis in the Brain

Normal Iron Metabolism

The brain requires iron for essential functions:

• Myelin production: Iron is a cofactor for oligodendrocyte myelination
• Neurotransmitter synthesis: Tyrosine hydroxylase and dopamine synthesis require iron
• Mitochondrial function: Iron-sulfur cluster biosynthesis
• DNA synthesis: Ribonucleotide reductase requires iron

Iron Dysregulation in Neurodegeneration

Multiple mechanisms contribute to iron accumulation in neurodegenerative diseases:

• Impaired iron export: Dysfunction of ferroportin (SLC40A1) and ceruloplasmin
• Increased iron uptake: Upregulation of transferrin receptor and DMT1
• Microglial iron release: Chronic neuroinflammation leads to iron accumulation
• [Blood-brain barrier](/entities/blood-brain-barrier) disruption: Permeability allows serum iron entry

Alzheimer's Disease

Iron Accumulation Patterns

Iron accumulates in:

• [Hippocampus](/brain-regions/hippocampus): Particularly in the CA1 region and subiculum
• Amyloid plaques: Co-localization with Aβ deposits
• Neurofibrillary tangles: Associated with hyperphosphorylated [tau](/proteins/tau)
• Basal forebrain cholinergic [neurons](/entities/neurons): Vulnerability to iron toxicity

Iron's Role in AD Pathogenesis

Redox-active iron contributes to AD through multiple mechanisms[@rottkamp2001]:

• [Amyloid-beta](/proteins/amyloid-beta) aggregation: Iron promotes Aβ oligomerization
• Tau hyperphosphorylation: Iron activates kinases including [GSK-3β](/entities/gsk3-beta)
• Lipid peroxidation: Iron catalyzes ROS formation in membranes
• Synaptic dysfunction: Iron-induced oxidative stress impairs neurotransmission

Chelation Therapy in AD

Clinical trials have evaluated iron chelators in AD:

• Deferoxamine (Desferal): Early trials showed slowed cognitive decline[@crapper1993]
• Clioquinol: Phase 2 trial demonstrated reduced cognitive decline[@ritchie2003]
• Deferasirox: Currently under investigation[@lovell2018]

Parkinson's Disease

Iron Accumulation Patterns

PD shows striking iron deposition:

• Substantia nigra pars compacta: Marked iron increase in dopaminergic neurons
• Globus pallidus: Iron accumulation in output nuclei
• Red nucleus: Iron deposits in motor-related structures

Iron's Role in PD Pathogenesis

Iron contributes to dopaminergic neuron death[@weinreb2007]:

• Mitochondrial dysfunction: Iron catalyzes Fenton reactions
• [Alpha-synuclein](/proteins/alpha-synuclein) aggregation: Iron promotes α-syn fibrillization
• Neuromelanin degradation: Releases stored iron
• Microglial activation: Iron amplifies neuroinflammation

Chelation Therapy in PD

Promising therapeutic approaches include:

• Deferoxamine: Neuroprotective in MPTP models[@benshlomo2007]
• Deferasirox: Phase 2 trial in PD patients showed reduced motor progression[@devos2014]
• Novel chelators: GPX-456 and others in development[@kaur2019]

Amyotrophic Lateral Sclerosis

Iron Dysregulation in ALS

ALS shows iron accumulation in:

• Motor [cortex](/brain-regions/cortex): Iron deposits in upper motor neurons
• Spinal cord: Motor neuron loss associated with iron
• Muscle: Elevated systemic iron markers

Iron's Role in ALS

Iron contributes to motor neuron injury[@orellana2016]:

• Oxidative stress: Increased ROS production
• Mitochondrial dysfunction: Impaired energy metabolism
• Excitotoxicity: Iron-glutamate interactions
• Protein aggregation: Enhanced misfolding

Iron Chelators in Clinical Use

Deferoxamine (Desferal)

• Administration: Subcutaneous infusion (preferred for brain delivery)
• Blood-brain barrier penetration: Limited, but clinical benefit observed
• Side effects: Ototoxicity, visual disturbances, injection site reactions
• Dosing: 20-40 mg/kg/day subcutaneously

Deferasirox (Exjade, Jadenu)

• Administration: Oral daily
• BBB penetration: Moderate
• Side effects: Gastrointestinal symptoms, rash, renal/hepatic function changes
• Advantages: Better compliance than deferoxamine

Clioquinol

• Mechanism: Metal-protein attenuating compound (MPAC)
• BBB penetration: Good
• Advantages: Modulates Aβ and α-syn aggregation
• Status: Phase 2/3 trials in AD and PD[@chen2020]

Novel Chelators in Development

M30

• Novel iron chelator with neuroprotective properties
• Activates Nrf2 pathway
• Modulates [autophagy](/entities/autophagy)
• Promising for AD and PD[@kalfon2017]

VK28

• Brain-penetrant iron chelator
• Antioxidant and anti-inflammatory effects
• Under investigation for PD[@zhang2019]

Glycine-Proline-Lysine (GPK)

• Tripeptide chelator
• Low systemic toxicity
• Currently in preclinical testing

Combination Approaches

Chelation Plus Antioxidants

• Alpha-lipoic acid: Synergistic oxidative stress reduction
• Coenzyme Q10: Mitochondrial protection
• Vitamin E: Lipid peroxidation prevention

Chelation Plus Anti-amyloid Therapy

• Combined Aβ/α-syn targeting with metal modulation
• Enhanced protein clearance
• Potential disease-modifying effects

Allen Brain Atlas Resources

• [Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions
• [Allen Brain Atlas - Cell Types](https://celltypes.brain-map.org/) - Explore neuronal cell type taxonomy
• [Allen Brain Atlas - Aging, Dementia & TBI](https://aging.brain-map.org/) - Data on aging and traumatic brain injury

See Also

• Iron Metabolism in the Brain
• [Oxidative Stress in Neurodegeneration](/mechanisms/oxidative-stress)
• [Alzheimer's Disease Treatments](/diseases/alzheimers-disease)
• [Parkinson's Disease Treatments](/diseases/parkinsons-disease)
• [Neuroinflammation in Neurodegeneration](/diseases/neurodegeneration)

Related Hypotheses

From the [SciDEX Exchange](/exchange) — scored by multi-agent debate

• [ACSL4-Driven Ferroptotic Priming in Disease-Associated Microglia](/hypothesis/h-seaad-v4-26ba859b) — <span style="color:#81c784;font-weight:600">0.73</span> · Target: ACSL4
• [Astrocytic Lipoxin A4 Pathway Restoration via ALOX15 Gene Therapy](/hypothesis/h-ac55ff26) — <span style="color:#ffd54f;font-weight:600">0.58</span> · Target: ALOX15
• [Nutrient-Sensing Epigenetic Circuit Reactivation](/hypothesis/h-4bb7fd8c) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: SIRT1
• [CYP46A1 Overexpression Gene Therapy](/hypothesis/h-2600483e) — <span style="color:#81c784;font-weight:600">0.79</span> · Target: CYP46A1
• [Gamma entrainment therapy to restore hippocampal-cortical synchrony](/hypothesis/h-bdbd2120) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SST
• [Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation](/hypothesis/h-9e9fee95) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: HCRTR1/HCRTR2
• [Selective Acid Sphingomyelinase Modulation Therapy](/hypothesis/h-de0d4364) — <span style="color:#81c784;font-weight:600">0.77</span> · Target: SMPD1
• [Membrane Cholesterol Gradient Modulators](/hypothesis/h-9d29bfe5) — <span style="color:#81c784;font-weight:600">0.76</span> · Target: ABCA1/LDLR/SREBF2

Related Analyses:

• [SEA-AD Gene Expression Profiling — Allen Brain Cell Atlas](/analysis/analysis-SEAAD-20260402) &#x1f504;
• [Senescent cell clearance as neurodegeneration therapy](/analysis/SDA-2026-04-02-gap-senescent-clearance-neuro) &#x1f504;
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v4-20260402065846) &#x1f504;
• [Cell type vulnerability in Alzheimers Disease (SEA-AD transcriptomic data)](/analysis/SDA-2026-04-02-gap-seaad-v3-20260402063622) &#x1f504;
• [Extracellular vesicle biomarkers for early AD detection](/analysis/SDA-2026-04-02-gap-ev-ad-biomarkers) &#x1f504;